Applied DNA Sciences exceeded Q3 EPS estimates by $1.11, but missed revenue targets, leading to stock price increase and mixed analyst ratings.
Applied DNA Sciences (APDN) reported Q3 earnings of $0.47 EPS, exceeding analysts' consensus estimates by $1.11. Despite generating $0.80M in revenue, falling short of the projected $0.95M, the firm's stock price increased by $0.01, reaching $0.36. HC Wainwright lowered their target price to $1.50 while maintaining a "buy" rating, while StockNews.com issued a "sell" rating. APDN operates in DNA production, testing services, and DNA tagging and security products and services.
August 11, 2024
3 Articles